Skip to main content
Top
Published in: Current Hematologic Malignancy Reports 4/2015

01-12-2015 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM

Authors: Naveen Pemmaraju, Vikas Gupta, Ruben Mesa, Michael A. Thompson

Published in: Current Hematologic Malignancy Reports | Issue 4/2015

Login to get access

Abstract

The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the field of hematology and oncology, a field which frequently experiences rapid shifts of information and novel, practice-changing discoveries. Among the many social media platforms available to cancer patients and providers, one platform in particular, Twitter, has become the focus for the creation of disease-specific communities, especially for those interested in, affected by, or those who perform research in the fields of rare cancers, which historically have had a dearth of reliable information available. This article will focus on the initiation and progress of one such Twitter hematology/oncology community, #mpnsm, which was originally created for the purpose of serving as a venue for improving the interaction among patients, providers, researchers, and organizations with interest in the myeloproliferative neoplasms (MPNs) and to further the availability of reliable up-to-date analysis; relevant expert commentary; and readily usable information for patients, providers, and other groups interested in this field.
Literature
2.
go back to reference Baptist AP, Thompson M, Grossman KS, Mohammed L, Sy A, Sanders GM. Social media, text messaging, and email-preferences of asthma patients between 12 and 40 years old. J Asthma. 2011;48:824–30.CrossRefPubMed Baptist AP, Thompson M, Grossman KS, Mohammed L, Sy A, Sanders GM. Social media, text messaging, and email-preferences of asthma patients between 12 and 40 years old. J Asthma. 2011;48:824–30.CrossRefPubMed
3.
go back to reference Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782, 4–5–91. Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782, 4–5–91.
4.
go back to reference Hawn C. Take two aspirin and tweet me in the morning: how Twitter, Facebook, and other social media are reshaping health care. Health Aff. 2009;28:361–8.CrossRef Hawn C. Take two aspirin and tweet me in the morning: how Twitter, Facebook, and other social media are reshaping health care. Health Aff. 2009;28:361–8.CrossRef
5.
go back to reference Scanfeld D, Scanfeld V, Larson EL. Dissemination of health information through social networks: twitter and antibiotics. Am J Infect Control. 2010;38:182–8.PubMedCentralCrossRefPubMed Scanfeld D, Scanfeld V, Larson EL. Dissemination of health information through social networks: twitter and antibiotics. Am J Infect Control. 2010;38:182–8.PubMedCentralCrossRefPubMed
6.
go back to reference Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17:e188.CrossRefPubMed Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17:e188.CrossRefPubMed
8.
go back to reference Lazard AJ, Scheinfeld E, Bernhardt JM, Wilcox GB, Suran M. Detecting themes of public concern: a text mining analysis of the centers for disease control and prevention’s Ebola live Twitter chat. Am J Infect Control. 2015;doi: 10.1016/j.ajic.2015.05.025. Lazard AJ, Scheinfeld E, Bernhardt JM, Wilcox GB, Suran M. Detecting themes of public concern: a text mining analysis of the centers for disease control and prevention’s Ebola live Twitter chat. Am J Infect Control. 2015;doi: 10.​1016/​j.​ajic.​2015.​05.​025.
9.
go back to reference Chaudhry A, Glode LM, Gillman M, Miller RS. Trends in twitter use by physicians at the American Society of Clinical Oncology annual meeting, 2010 and 2011. J Oncol Pract. 2012;8:173–8.PubMedCentralCrossRefPubMed Chaudhry A, Glode LM, Gillman M, Miller RS. Trends in twitter use by physicians at the American Society of Clinical Oncology annual meeting, 2010 and 2011. J Oncol Pract. 2012;8:173–8.PubMedCentralCrossRefPubMed
10.
go back to reference Nwosu AC, Debattista M, Rooney C, Mason S. Social media and palliative medicine: a retrospective 2-year analysis of global Twitter data to evaluate the use of technology to communicate about issues at the end of life. BMJ Support Palliat Care. 2015;5:207–12.CrossRefPubMed Nwosu AC, Debattista M, Rooney C, Mason S. Social media and palliative medicine: a retrospective 2-year analysis of global Twitter data to evaluate the use of technology to communicate about issues at the end of life. BMJ Support Palliat Care. 2015;5:207–12.CrossRefPubMed
11.
go back to reference Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
12.
go back to reference Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.PubMed Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.PubMed
13.
go back to reference O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.CrossRefPubMed O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.CrossRefPubMed
14.
go back to reference Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.PubMedCentralCrossRefPubMed Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.PubMedCentralCrossRefPubMed
15.
go back to reference Pemmaraju N, Moliterno AR. From Philadelphia-negative to JAK2-Positive: effect of genetic discovery on risk stratification and management. Am Soc Clin Oncol Educ Book. 2015;35:139–45.CrossRef Pemmaraju N, Moliterno AR. From Philadelphia-negative to JAK2-Positive: effect of genetic discovery on risk stratification and management. Am Soc Clin Oncol Educ Book. 2015;35:139–45.CrossRef
16.
go back to reference Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed
17.
go back to reference Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.CrossRefPubMed Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.CrossRefPubMed
18.
go back to reference Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed
19.
go back to reference Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed
20.
21.
go back to reference Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.PubMedCentralCrossRefPubMed Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.PubMedCentralCrossRefPubMed
22.
go back to reference Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMed Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMed
23.
go back to reference Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–901.CrossRefPubMed Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–901.CrossRefPubMed
24.
go back to reference Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.CrossRefPubMed Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.CrossRefPubMed
25.
go back to reference Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.CrossRefPubMed Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.CrossRefPubMed
26.
go back to reference Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.CrossRefPubMed Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.CrossRefPubMed
27.
go back to reference Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124:3529–37.CrossRefPubMed Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124:3529–37.CrossRefPubMed
28.
go back to reference Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–8.CrossRefPubMed Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–8.CrossRefPubMed
29.
go back to reference Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.CrossRefPubMed Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.CrossRefPubMed
30.
go back to reference Cartledge P, Miller M, Phillips B. The use of social-networking sites in medical education. Med Teach. 2013;35:847–57.CrossRefPubMed Cartledge P, Miller M, Phillips B. The use of social-networking sites in medical education. Med Teach. 2013;35:847–57.CrossRefPubMed
31.
go back to reference McGowan BS, Wasko M, Vartabedian BS, Miller RS, Freiherr DD, Abdolrasulnia M. Understanding the factors that influence the adoption and meaningful use of social media by physicians to share medical information. J Med Internet Res. 2012;14:e117.PubMedCentralCrossRefPubMed McGowan BS, Wasko M, Vartabedian BS, Miller RS, Freiherr DD, Abdolrasulnia M. Understanding the factors that influence the adoption and meaningful use of social media by physicians to share medical information. J Med Internet Res. 2012;14:e117.PubMedCentralCrossRefPubMed
32.
go back to reference Wilkinson SE, Basto MY, Perovic G, Lawrentschuk N, Murphy DG. The social media revolution is changing the conference experience: analytics and trends from eight international meetings. BJU Int. 2015;115:839–46.CrossRefPubMed Wilkinson SE, Basto MY, Perovic G, Lawrentschuk N, Murphy DG. The social media revolution is changing the conference experience: analytics and trends from eight international meetings. BJU Int. 2015;115:839–46.CrossRefPubMed
33.
go back to reference Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:suppl abstr 6520. Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:suppl abstr 6520.
34.
go back to reference Bahkali S, Almaiman A, Bahkali A, Almaiman S, Househ M, Alsurimi K. The role of social media in promoting women’s health education in Saudi Arabia. Stud Health Technol Inform. 2015;213:259–62.PubMed Bahkali S, Almaiman A, Bahkali A, Almaiman S, Househ M, Alsurimi K. The role of social media in promoting women’s health education in Saudi Arabia. Stud Health Technol Inform. 2015;213:259–62.PubMed
35.
36.
37.
go back to reference Kitching F, Winbolt M, MacPhail A, Ibrahim JE. Web-based social media for professional medical education: perspectives of senior stakeholders in the nursing home sector. Nurse Educ Today. 2015; doi:10.1016/j.nedt.2015.05.013. Kitching F, Winbolt M, MacPhail A, Ibrahim JE. Web-based social media for professional medical education: perspectives of senior stakeholders in the nursing home sector. Nurse Educ Today. 2015; doi:10.​1016/​j.​nedt.​2015.​05.​013.
38.
go back to reference Jalali A, Sherbino J, Frank J, Sutherland S. Social media and medical education: exploring the potential of Twitter as a learning tool. Int Rev Psychiatry. 2015;27:140–6.CrossRefPubMed Jalali A, Sherbino J, Frank J, Sutherland S. Social media and medical education: exploring the potential of Twitter as a learning tool. Int Rev Psychiatry. 2015;27:140–6.CrossRefPubMed
39.
go back to reference Chan TM, Thoma B, Lin M. Creating, curating, and sharing online faculty development resources: the medical education in cases series experience. Acad Med. 2015;90:785–9.CrossRefPubMed Chan TM, Thoma B, Lin M. Creating, curating, and sharing online faculty development resources: the medical education in cases series experience. Acad Med. 2015;90:785–9.CrossRefPubMed
41.
go back to reference Bell JA, Balneaves LG. Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy. Support Care Cancer. 2015;23:1169–96.CrossRefPubMed Bell JA, Balneaves LG. Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy. Support Care Cancer. 2015;23:1169–96.CrossRefPubMed
42.
go back to reference Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015; doi:10.1002/ajh.24098. Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015; doi:10.​1002/​ajh.​24098.
43.
go back to reference Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015;56:1989–99.CrossRefPubMed Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015;56:1989–99.CrossRefPubMed
44.
go back to reference Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematol Malig Rep. 2014;9:324–30.CrossRefPubMed Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematol Malig Rep. 2014;9:324–30.CrossRefPubMed
45.
47.
go back to reference Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27:1852–60.CrossRefPubMed Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27:1852–60.CrossRefPubMed
48.
go back to reference Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125:499–503.CrossRefPubMed Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125:499–503.CrossRefPubMed
49.
go back to reference Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125:2649–55.PubMedCentralCrossRefPubMed Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125:2649–55.PubMedCentralCrossRefPubMed
50.
go back to reference Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.PubMedCentralCrossRefPubMed Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.PubMedCentralCrossRefPubMed
51.
go back to reference Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373:908–19.CrossRefPubMed Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373:908–19.CrossRefPubMed
52.
go back to reference Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–8.CrossRefPubMed Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–8.CrossRefPubMed
53.
go back to reference Armanios M, Greider CW. Treating myeloproliferation—on target or off? N Engl J Med. 2015;373:965–6.CrossRefPubMed Armanios M, Greider CW. Treating myeloproliferation—on target or off? N Engl J Med. 2015;373:965–6.CrossRefPubMed
Metadata
Title
Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM
Authors
Naveen Pemmaraju
Vikas Gupta
Ruben Mesa
Michael A. Thompson
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 4/2015
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-015-0287-9

Other articles of this Issue 4/2015

Current Hematologic Malignancy Reports 4/2015 Go to the issue

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Molecular Pathogenesis of Peripheral T Cell Lymphoma

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy